Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S.
Nygren P, et al. Among authors: ahmed t.
Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16. doi: 10.1007/s00280-004-0946-3. Epub 2005 Feb 19.
Cancer Chemother Pharmacol. 2005.
PMID: 15723220
Clinical Trial.